APLS Q3 2023 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$110M+400.5% YoY

Gross Profit

$88M79.7% margin

Operating Income

-$137M-124.2% margin

Net Income

-$140M-127.0% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

+16.2%

Cash Flow

Operating Cash Flow

-$169M

Free Cash Flow

-$169M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$818M

Total Liabilities

$586M

Stockholders' Equity

$232M

Cash & Equivalents

$452M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$110M	$22M	+400.5%
Gross Profit	$88M	$21M	+325.6%
Operating Income	-$137M	-$153M	+10.4%
Net Income	-$140M	-$191M	+26.7%

Revenue Segments

Product

$99M90%

Licensing And Other Revenue

$11M10%